A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

Phase 1

Waitlist Available

Led By Siqing Fu

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial examines the side effects and optimal dose of SOR-C13 in patients with advanced solid tumors that have not responded to other treatments. SOR-C13 aims to block a pathway in cancer cells to prevent their growth and spread.

Eligible Conditions

Pancreatic Cancer
Ovarian Cancer
Prostate Cancer
Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of adverse events and serious adverse events

Secondary study objectives

Clinical benefit

Objective responses

Predictive biomarkers

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (TRPV6 calcium channel inhibitor SOR-C13)Experimental Treatment1 Intervention

Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

SOR-C13

Not yet FDA approved

Do I qualify?Apply below to find out